Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial
- PMID: 10372241
- DOI: 10.2337/diacare.22.6.913
Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in type 2 diabetes. A randomized controlled metabolic trial
Abstract
Objective: To examine whether Konjac-mannan (KJM) fiber improves metabolic control as measured by glycemia, lipidemia, and blood pressure in high-risk type 2 diabetic patients.
Research design and methods: A total of 11 hyperlipidemic and hypertensive type 2 diabetic patients treated conventionally by a low-fat diet and drug therapy participated. After an 8-week baseline, all were randomly assigned to take either KJM fiber-enriched test biscuits (0.7 g/412 kJ [100 kcal] of glucomannan) or matched placebo wheat bran fiber biscuits during two 3-week treatment phases separated by a 2-week washout period. The diet in either case was metabolically controlled and conformed to National Cholesterol Education Program Step 2 guidelines, while medications were maintained constant. Efficacy measures included serum fructosamine, lipid profiles, apolipoproteins, blood pressure, body weight, and nutritional analysis.
Results: Compared with placebo, KJM significantly reduced the metabolic control primary end points: serum fructosamine (5.7%, P = 0.007, adjusted alpha = 0.0167), total:HDL cholesterol ratio (10%, P = 0.03, adjusted alpha = 0.05), and systolic blood pressure (sBP) (6.9%, P = 0.02, adjusted alpha = 0.025). Secondary end points, including body weight, total, LDL, and HDL cholesterol, triglycerides, apolipoproteins A-1, B, and their ratio, glucose, insulin, and diastolic blood pressure, were not significant after adjustment by the Bonferroni-Hochberg procedure.
Conclusions: KJM fiber added to conventional treatment may ameliorate glycemic control, blood lipid profile, and sBP in high-risk diabetic individuals, possibly improving the effectiveness of conventional treatment in type 2 diabetes.
Similar articles
-
Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled metabolic trial.Diabetes Care. 2000 Jan;23(1):9-14. doi: 10.2337/diacare.23.1.9. Diabetes Care. 2000. PMID: 10857960 Clinical Trial.
-
A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B.Am J Clin Nutr. 2017 May;105(5):1239-1247. doi: 10.3945/ajcn.116.142158. Epub 2017 Mar 29. Am J Clin Nutr. 2017. PMID: 28356275 Review.
-
Placebo-controlled trial of the effects of guar gum and metformin on fasting blood glucose and serum lipids in obese, type 2 diabetic patients.Diabet Med. 1990 Mar-Apr;7(3):242-5. doi: 10.1111/j.1464-5491.1990.tb01378.x. Diabet Med. 1990. PMID: 2158410 Clinical Trial.
-
Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.Diabetes Care. 1998 Aug;21(8):1288-94. doi: 10.2337/diacare.21.8.1288. Diabetes Care. 1998. PMID: 9702435 Clinical Trial.
-
[Comparison of guar gum, wheat bran and placebo on carbohydrate and lipid metabolism in type II diabetics].Schweiz Med Wochenschr. 1990 Mar 24;120(12):402-8. Schweiz Med Wochenschr. 1990. PMID: 2157279 Review. German.
Cited by 20 articles
-
Konjac glucomannan reverses multi-drug resistance of HepG2/5-FU cells by suppressing AKT signaling and increasing p53 expression.Oncol Lett. 2020 Sep;20(3):2105-2112. doi: 10.3892/ol.2020.11790. Epub 2020 Jul 1. Oncol Lett. 2020. PMID: 32782527 Free PMC article.
-
Gastrointestinal and metabolic effects of noodles-based konjac glucomannan in rats.Food Nutr Res. 2019 Dec 13;63. doi: 10.29219/fnr.v63.1997. eCollection 2019. Food Nutr Res. 2019. PMID: 31903092 Free PMC article.
-
Co-administration of a konjac-based fibre blend and American ginseng (Panax quinquefolius L.) on glycaemic control and serum lipids in type 2 diabetes: a randomized controlled, cross-over clinical trial.Eur J Nutr. 2018 Sep;57(6):2217-2225. doi: 10.1007/s00394-017-1496-x. Epub 2017 Jul 7. Eur J Nutr. 2018. PMID: 28687934 Clinical Trial.
-
Glucomannan- and glucomannan plus spirulina-enriched pork affect liver fatty acid profile, LDL receptor expression and antioxidant status in Zucker fa/fa rats fed atherogenic diets.Food Nutr Res. 2016 Dec 20;61(1):1264710. doi: 10.1080/16546628.2017.1264710. eCollection 2017. Food Nutr Res. 2016. PMID: 28325998 Free PMC article.
-
Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes.Open Heart. 2015 Oct 19;2(1):e000327. doi: 10.1136/openhrt-2015-000327. eCollection 2015. Open Heart. 2015. PMID: 26512331 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
-
Full Text Sources
-
Other Literature Sources
-
Medical